← Back to Search

Antioxidant

Active Treatment for Coronavirus

Phase 2 & 3
Waitlist Available
Research Sponsored by Adamis Pharmaceuticals Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7,14 and 21 days from the date randomization/first dosing.
Awards & highlights

Study Summary

This trial will test whether the drug Tempol can help people with COVID-19. The trial is double-blind, meaning that neither the participants nor the researchers will know who is receiving the drug or the placebo.

Eligible Conditions
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7,14 and 21 days from the date randomization/first dosing.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7,14 and 21 days from the date randomization/first dosing. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Difference in the rate of sustained clinical resolution1 of symptoms of COVID-19
Secondary outcome measures
Changes in functional status: Post COVID Functional Scale (PCFS)
Efficacy of Tempol on preventing hospitalization: Odds ratio of the rate of hospitalization
Safety of Tempol + SOC vs placebo + SOC: Occurrence of Adverse Events/All cause of mortality

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active TreatmentActive Control1 Intervention
Tempol (MMB-02) 800 mg per Day (n=124)
Group II: PlaceboPlacebo Group1 Intervention
Placebo (n=124)

Find a Location

Who is running the clinical trial?

Adamis Pharmaceuticals CorporationLead Sponsor
3 Previous Clinical Trials
60 Total Patients Enrolled
Ronald B Moss, MDStudy DirectorAdamis Pharmaceutical Corporation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.
2021. "Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04729595.
~69 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top